BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 32648041)

  • 21. BRAF VE1 immunoreactivity patterns in epithelioid glioblastomas positive for BRAF V600E mutation.
    Kleinschmidt-DeMasters BK; Aisner DL; Foreman NK
    Am J Surg Pathol; 2015 Apr; 39(4):528-40. PubMed ID: 25581727
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeted therapy for BRAFV600E malignant astrocytoma.
    Nicolaides TP; Li H; Solomon DA; Hariono S; Hashizume R; Barkovich K; Baker SJ; Paugh BS; Jones C; Forshew T; Hindley GF; Hodgson JG; Kim JS; Rowitch DH; Weiss WA; Waldman TA; James CD
    Clin Cancer Res; 2011 Dec; 17(24):7595-604. PubMed ID: 22038996
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Response to combined BRAF/MEK inhibition in adult BRAF V600E mutant spinal pilocytic astrocytoma.
    Balasubramanian A; Gunjur A; Gan HK; Perchyonok Y; Cher LM
    J Clin Neurosci; 2020 Sep; 79():269-271. PubMed ID: 33070910
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Implications of BRAF V600E mutation in gliomas: Molecular considerations, prognostic value and treatment evolution.
    Di Nunno V; Gatto L; Tosoni A; Bartolini S; Franceschi E
    Front Oncol; 2022; 12():1067252. PubMed ID: 36686797
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dysembryoplastic neuroepithelial tumors share with pleomorphic xanthoastrocytomas and gangliogliomas BRAF(V600E) mutation and expression.
    Chappé C; Padovani L; Scavarda D; Forest F; Nanni-Metellus I; Loundou A; Mercurio S; Fina F; Lena G; Colin C; Figarella-Branger D
    Brain Pathol; 2013 Sep; 23(5):574-83. PubMed ID: 23442159
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BRAF V600E-mutated central nervous system tumor with divergent morphological feature - Anaplastic pleomorphic xanthoastrocytoma-like and astroblastoma-like.
    Purkait S; Bansal S; Malgulwar PB
    Neuropathology; 2019 Feb; 39(1):64-67. PubMed ID: 30557911
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BRAF/MEK Dual Inhibitors Therapy in Progressive and Anaplastic Pleomorphic Xanthoastrocytoma: Case Series and Literature Review.
    Kata K; Rodriguez-Quintero JC; Arevalo OD; Zhang JJ; Bhattacharjee MB; Ware C; Dono A; Riascos-Castaneda R; Tandon N; Blanco A; Esquenazi Y; Ballester LY; Amsbaugh M; Day AL; Zhu JJ
    J Natl Compr Canc Netw; 2022 Nov; 20(11):1193-1202.e6. PubMed ID: 36351333
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Integrated genotype-phenotype analysis of long-term epilepsy-associated ganglioglioma.
    Wang Y; Wang L; Blümcke I; Zhang W; Fu Y; Shan Y; Piao Y; Zhao G
    Brain Pathol; 2022 Jan; 32(1):e13011. PubMed ID: 34355449
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical relevance of BRAF status in glial and glioneuronal tumors: A systematic review.
    Sugiura Y; Nagaishi M
    J Clin Neurosci; 2019 Aug; 66():196-201. PubMed ID: 31147232
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The genetic landscape of ganglioglioma.
    Pekmezci M; Villanueva-Meyer JE; Goode B; Van Ziffle J; Onodera C; Grenert JP; Bastian BC; Chamyan G; Maher OM; Khatib Z; Kleinschmidt-DeMasters BK; Samuel D; Mueller S; Banerjee A; Clarke JL; Cooney T; Torkildson J; Gupta N; Theodosopoulos P; Chang EF; Berger M; Bollen AW; Perry A; Tihan T; Solomon DA
    Acta Neuropathol Commun; 2018 Jun; 6(1):47. PubMed ID: 29880043
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BRAF V600E-mutated diffuse glioma in an adult patient: a case report and review.
    Suzuki Y; Takahashi-Fujigasaki J; Akasaki Y; Matsushima S; Mori R; Karagiozov K; Joki T; Ikeuchi S; Ikegami M; Manome Y; Murayama Y
    Brain Tumor Pathol; 2016 Jan; 33(1):40-9. PubMed ID: 26445861
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epithelioid GBMs show a high percentage of BRAF V600E mutation.
    Kleinschmidt-DeMasters BK; Aisner DL; Birks DK; Foreman NK
    Am J Surg Pathol; 2013 May; 37(5):685-98. PubMed ID: 23552385
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A clinicopathologic study of diencephalic pediatric low-grade gliomas with BRAF V600 mutation.
    Ho CY; Mobley BC; Gordish-Dressman H; VandenBussche CJ; Mason GE; Bornhorst M; Esbenshade AJ; Tehrani M; Orr BA; LaFrance DR; Devaney JM; Meltzer BW; Hofherr SE; Burger PC; Packer RJ; Rodriguez FJ
    Acta Neuropathol; 2015 Oct; 130(4):575-85. PubMed ID: 26264609
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Durable Progression-Free Survival With the Use of BRAF and MEK Inhibitors in Four Cases With
    Fusco MJ; Piña Y; Macaulay RJ; Sahebjam S; Forsyth PA; Peguero E; Walko CM
    Cancer Control; 2021; 28():10732748211040013. PubMed ID: 34620004
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel, potentially targetable TMEM106B-BRAF fusion in pleomorphic xanthoastrocytoma.
    Hsiao SJ; Karajannis MA; Diolaiti D; Mansukhani MM; Bender JG; Kung AL; Garvin JH
    Cold Spring Harb Mol Case Stud; 2017 Mar; 3(2):a001396. PubMed ID: 28299358
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BRAF V600E expression and distribution in desmoplastic infantile astrocytoma/ganglioglioma.
    Koelsche C; Sahm F; Paulus W; Mittelbronn M; Giangaspero F; Antonelli M; Meyer J; Lasitschka F; von Deimling A; Reuss D
    Neuropathol Appl Neurobiol; 2014 Apr; 40(3):337-44. PubMed ID: 23822828
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical response to dabrafenib plus trametinib in a pediatric ganglioglioma with
    Miller KE; Schieffer KM; Grischow O; Rodriguez DP; Cottrell CE; Leonard JR; Finlay JL; Mardis ER
    Cold Spring Harb Mol Case Stud; 2021 Apr; 7(2):. PubMed ID: 33637608
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunohistochemistry is highly sensitive and specific for detection of BRAF V600E mutation in pleomorphic xanthoastrocytoma.
    Ida CM; Vrana JA; Rodriguez FJ; Jentoft ME; Caron AA; Jenkins SM; Giannini C
    Acta Neuropathol Commun; 2013 May; 1():20. PubMed ID: 24252190
    [TBL] [Abstract][Full Text] [Related]  

  • 39. V600E BRAF mutation in pilocytic astrocytoma is associated with a more diffuse growth pattern but does not confer a more aggressive clinical behavior.
    Bannykh SI; Mirocha J; Nuno M; Lopategui J; Kandala G
    Clin Neuropathol; 2014; 33(6):388-98. PubMed ID: 25066317
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular characterization of disseminated pilocytic astrocytomas.
    Gessi M; Engels AC; Lambert S; Rothämel T; von Hornstein S; Collins VP; Denkhaus D; Gnekow A; Pietsch T
    Neuropathol Appl Neurobiol; 2016 Apr; 42(3):273-8. PubMed ID: 26084390
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.